Loading stock data…
$122.86-5.65 (-4.40%)
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
Palvella Therapeutics, Inc. in the Healthcare sector is trading at $122.86 with a market capitalization of $2.2B. Wall Street consensus targets $228.93 (15 analysts), implying a +86.3% move over the next 12 months. The stock is currently 24% below its 52-week high of $161.38, remaining 1.7% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$21.41M↓ | -$14.86M↓ | -$11.30M↓ | -$10.18M↓ | -$9.25M |
| Net Income | -$21.87M↓ | -$15.77M↓ | -$12.71M↓ | -$11.35M↓ | -$9.47M |
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a n...